PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PVCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PVCT
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies, primarily its lead drug candidate PV-10, and faces significant financial challenges with a going concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for PROVECTUS BIOPHARMACEUTICALS, INC..
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies, primarily its lead drug candidate PV-10, and faces significant financial challenges with a going concern risk.
- Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing therapies for cancer, with its lead candidate PV-10 [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash and equivalents of $1.2M, a net loss of $1.0M, negative shareholders' equity of -$5.9M, and total debt of $0.1M [sec].
- The company has a history of net losses and an accumulated deficit, and management has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-13].
- Provectus has significant convertible debt obligations, including $3,310,179 in 2025 Convertible Notes Payable that automatically convert to preferred stock at maturity [sec_mda · as of 2026-08-13].
- Management plans to raise capital through equity offerings, debt financings, or collaborations, but there is no assurance of success [sec_mda · as of 2026-08-13].
What works
- The company is selectively continuing ongoing and planning to initiate new monotherapy and/or combination clinical trials for its lead candidate PV-10 [sec_mda · as of 2026-03-26].
- Management's primary business objective is to build the company into a commercial-stage biotechnology company [sec_mda · as of 2026-03-26].
What to weigh
- The company has a very limited cash position of $1.2M as of June 30, 2026, which is insufficient to fund ongoing operations and clinical trials without additional financing [sec].
- Provectus has negative shareholders' equity of -$5.9M as of June 30, 2026, indicating a weak financial position [sec].
- The company faces significant debt obligations, including $3,310,179 in convertible notes, and has stated that if it cannot raise capital, it will not be able to pay its obligations as they become due [sec_mda · as of 2026-08-13].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, and there is no assurance that financing efforts will be successful [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
The company has a going concern risk and needs to raise capital to continue operations.
“Management's plans include selling our equity securities and obtaining other financing, including the issuance of 2025 unsecured convertible notes (the "2025 Financing"), to fund our capital requirements and on-going operations; however, there can be no assurance that the Company will be successful in these efforts.”
SEC MD&A · August 13, 2026
The company has significant convertible debt that converts to preferred stock at maturity.
“in the aggregate amount of $3,310,179 owed in connection with 2025 Convertible Notes Payable automatically convert to preferred stock at maturity and are only subject to repayment in the event of a change of control or event of default.”
SEC MD&A · August 13, 2026
The company's primary business objective is to become a commercial-stage biotechnology company.
“The primary business objective of management is to build the Company into a commercial-stage biotechnology company”
SEC MD&A · March 26, 2026
The company is continuing and planning new clinical trials.
“The Company is selectively continuing ongoing and planning to initiate new monotherapy and/or”
SEC MD&A · March 26, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has expressed substantial doubt about the company's ability to continue as a going concern due to limited cash and need for additional financing [sec_mda · as of 2026-08-13].
- Cash runway insufficient — Cash of $1.2M as of June 30, 2026 is insufficient to fund operations and clinical trials without new capital [sec].
- Debt conversion risk — The company has $3.3M in convertible notes that convert to preferred stock, diluting existing shareholders [sec_mda · as of 2026-08-13].
- Financing uncertainty — There is no assurance that the company will successfully raise capital through equity offerings, debt, or collaborations [sec_mda · as of 2026-08-13].
What to watch
- Ability to raise additional capital through equity offerings, debt financings, or collaborations [sec_mda · as of 2026-08-13].
- Progress of ongoing and planned clinical trials for PV-10 [sec_mda · as of 2026-03-26].
- Conversion or maturity of the 2025 Convertible Notes Payable [sec_mda · as of 2026-08-13].
- Any updates on the company's ability to continue as a going concern [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run PROVECTUS BIOPHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROVECTUS BIOPHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
10.2 months
OCF -$358K · Net income -$983K
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 0.8%
- Days to cover
- 0.5
- Shares short
- 1,821,793
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PVCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for PROVECTUS BIOPHARMACEUTICALS, INC.?
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies, primarily its lead drug candidate PV-10, and faces significant financial challenges with a going concern risk.
Who is the CEO of PROVECTUS BIOPHARMACEUTICALS, INC.?
Mr. Edward V. Pershing CPA is the chief executive officer of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
Where is PROVECTUS BIOPHARMACEUTICALS, INC. headquartered?
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) is headquartered in Knoxville, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.